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Steroids have a plausible mechanism of action of reducing severity of lung disease in 
acute respiratory distress syndrome (ARDS) but have failed to show consistent benefits 
in patient-centered outcomes. Many studies have confounding from the likely pres-
ence of ventilator-induced lung injury and steroids may have shown benefit because 
administration minimized ongoing inflammation incited by injurious ventilator settings. If 
steroids have benefit, it is likely for specific populations that fall within the heterogeneous 
diagnosis of ARDS. Those pediatric patients with concurrent active asthma or reactive 
airway disease of prematurity, in addition to ARDS, are the most common group likely 
to derive benefit from steroids, but are poorly studied. With the information currently 
available, it does not appear that the typical adult or pediatric patient with ARDS derives 
benefit from steroids and steroids should not be given on a routine basis.
Keywords: pediatric ARDS, steroids, mortality, ventilator-free days, heterogeneity
iNTRODUCTiON
It is widely accepted among intensivists that dysregulated inflammation in response to an inciting 
infection or injury is a key pathophysiologic feature of acute respiratory distress syndrome (ARDS). 
Glucocorticoids have known effects in dampening many aspects of the immune and inflammatory 
response and, therefore, it is biologically plausible that steroids would minimize disease severity in 
the patient with ARDS. Although the administration of corticosteroids for anti-inflammatory effect 
is an intuitive, widely available, and inexpensive therapy for ARDS, the receipt of steroids has not 
decreased mortality or improved other patient-centered outcomes. Despite a plausible mechanism 
of action, steroid treatment has also failed to show consistent benefit in other inflammatory disease 
processes, such as sepsis (1), indicating a fundamental challenge in the appropriate use of this class 
of medications for inflammatory disorders. The challenge remains poorly characterized with many 
hypotheses as to why steroids have not provided benefit for ARDS. Perhaps steroids are administered 
too late in the inflammatory process where redundant mechanisms of activation allow for ongoing 
pulmonary damage. Perhaps the paths to ARDS are significantly heterogeneous such that some 
subgroups would benefit from steroids, while others experience harm, and studying these groups 
together blurs the treatment effects.
Although the cumulative literature cannot endorse the routine use of steroids for ARDS, they 
are frequently prescribed – ~40% of patients received corticosteroids in several large trials (2, 3). 
Perhaps steroids remain in the intensivists’ armamentarium for ARDS because there are currently 
few alternative therapies to minimize pulmonary inflammation and maladaptive fibrotic repair 
2Hartmann and Hough Avoid Steroids for Pediatric ARDS
Frontiers in Pediatrics | www.frontiersin.org July 2016 | Volume 4 | Article 79
mechanisms. A better understanding of how patients’ lungs are 
able to control inflammation and recreate functional tissue will 
likely offer avenues of therapy in future years.
In general, there are three indications for which steroids may 
be considered for the patient with ARDS: (1) treatment of a coex-
istent steroid-responsive disease, (2) treatment of inflammation 
early in the course of ARDS to minimize lung damage, and (3) 
treatment of maladaptive healing responses late in the course of 
ARDS to improve lung function. Studies involving each group 
are considered separately and discussed below. Pediatric data are 
highlighted when available. Lastly, adult studies exploring the 
possible association of steroids with neuromuscular weakness 
are reviewed as a cautionary note that we may not understand all 
of the risks associated with steroid therapy. No similar pediatric 
data exist. Currently, practitioners have to decide if the potential 
benefits of steroids to treat ARDS outweigh possible risks of both 
short- and long-term morbidities using incomplete data. In most 
cases of ARDS, steroid therapy is unlikely to provide improved 
patient outcomes.
TReATMeNT OF CO-eXiSTiNG  
STeROiD-ReSPONSive DiSeASeS
Steroids may be prescribed to patients with ARDS to treat 
chronic pulmonary disorders that complicate the treatment of 
lung disease. This is a poorly studied group of patients but with 
a strong physiologic rationale for steroid treatment. Steroids 
alternatively may be prescribed to patients with ARDS with an 
acute process thought to be independently treatable with gluco-
corticoid therapy. This group of disorders includes diagnoses, 
such as community-acquired pneumonia (CAP), some etiolo-
gies of diffuse alveolar hemorrhage, and Pneumocystis jirovecii 
pneumonia. Only CAP will be discussed in detail as it is the 
most commonly encountered diagnosis and is a key risk factor 
for ARDS.
It is likely that there is a notable minority of patients with 
ARDS who have underlying chronic pulmonary diseases that are 
routinely treated with steroids. These include the familiar exam-
ples of chronic obstructive pulmonary disease (COPD) or asthma 
in adults and reactive airway disease and chronic lung disease 
of prematurity in the pediatric population. Based on reported 
numbers of ARDS patients who met inclusion criteria for large 
randomized controlled trials, ~9–15% were excluded for “chronic 
pulmonary disease” (4, 5), some of whom likely have diagnoses 
that respond positively to steroid therapy. A single institution 
prospective cohort of patients with moderate-to-severe pediatric 
ARDS (PARDS) noted that 15% had reactive airway disease 
and most of these patients received steroids (6). Based on these 
numbers, it is relatively common to have patients with ARDS who 
may have an active co-existing steroid-responsive disease.
Although the cohort with exacerbations of obstructive lung 
disease who meet consensus definitions of ARDS/PARDS are 
the most logical group to treat with glucocorticoids, this popula-
tion is poorly studied. Many of the large randomized controlled 
trials in adults that have shaped the way ARDS is treated today 
have excluded patients with “severe chronic respiratory disease” 
(4, 7–9). This group is captured as those with pre-existing 
hypercarbia, spirometry consistent with obstructive lung disease, 
home supplemental oxygen or non-invasive positive pressure 
ventilation, radiographic changes of obstructive lung disease, or 
some combination of these criteria. Other studies have excluded 
this cohort by excluding concurrent beta-2 agonist therapy (10). 
These definitions likely exclude some, but not all, patients with 
underlying steroid-responsive diseases. As such, the current 
ARDS literature does not help evaluate the spectrum of patients 
who may be experiencing concurrent steroid-responsive obstruc-
tive lung disease while hospitalized with ARDS. Similarly, in the 
pediatric literature patients with potentially steroid-responsive 
chronic disorders have been excluded in some studies and 
included in others without reporting the presence of these diag-
noses. For example, a study of surfactant for PARDS excluded 
children with status asthmaticus and chronic lung disease defined 
as use of home supplemental oxygen or diuretic medications (11). 
Another study of prone positioning did not specifically exclude 
children with potential steroid-responsive diseases, but did not 
report whether these patients were enrolled (12).
Adults receiving steroids for other underlying diseases, 
including recent asthma exacerbation, have been appropriately 
excluded from trials specifically for the evaluation of steroids 
in ARDS (5). A feasibility trial of steroids for PARDS included 
patients with asthma or potential prematurity-associated chronic 
lung disease and they comprised 20% of a small cohort (13), 
which may skew the results in a favorable direction for the use of 
steroids in PARDS. Any future investigation of steroids to treat 
ARDS should analyze patients with steroid-responsive chronic 
lung disease separately, as it is a challenge to understand the 
degree of impact steroids have on the obstructive vs. restrictive 
lung disease components of illness. These patients with active 
asthma, COPD, or prematurity-associated chronic lung disease 
complicating ARDS have the strongest rationale to have a posi-
tive response to routine steroid administration and may have the 
most optimal risk-benefit ratio among the three general indica-
tions for steroids.
Steroid administration has also been investigated to treat 
acute pulmonary disorders that are risk factors for ARDS. Two 
recent meta-analyses have reviewed randomized controlled 
trials and cohort studies that both concluded that there is a 
lower risk of ARDS when low-moderate doses of steroids are 
given in patients with CAP (14, 15). One review noted that 
average dosing of steroids for treatment of CAP to be lower 
than doses used to treat both early and late ARDS in many 
studies (15). Although there is a positive relationship between 
steroids and CAP, the finding does not indicate that steroids 
should be effective for patients with ARDS secondary to CAP, 
as this patient population is different by virtue of experiencing 
more robust pulmonary inflammation. There may be a “window 
of opportunity” in which steroids may benefit CAP to prevent 
progression to ARDS, but steroids probably are not useful once 
a patient has significant enough disease to meet ARDS criteria. 
The difference in the literature of steroid treatment for CAP vs. 
steroid treatment for ARDS highlights the importance of timing 
of steroid therapy. Many patients with ARDS likely present to 
medical attention beyond a potential “window of opportunity” 
for positive steroid effect.
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In summary, there is a high likelihood that steroid administra-
tion to patients with ARDS/PARDS with coexistent and active 
asthma, reactive airway disease associated with prematurity, or 
COPD will be beneficial based on the known pathophysiologic 
mechanisms of obstructive lung disorders. However, there is 
a paucity of clinical evidence to support this hypothesis. It is 
unlikely that steroids to treat acute pneumonia will improve 
outcome once patients have met criteria for ARDS as the timing 
of steroid administration is too late to mitigate the severity of 
inflammation.
TReATMeNT OF eARLY ARDS TO 
MiNiMiZe PULMONARY iNFLAMMATiON
Administration of steroids within the first 72 h of mechanical ven-
tilation for ARDS aims to dampen the exuberant inflammatory 
response and translate into milder pulmonary disease, marked 
by an increase in ventilator-free days and lower mortality. The 
majority of data for treatment of early ARDS with steroids were 
gathered when ventilator strategies likely incurred significant 
lung injury that impacted both clinical outcomes of mortality and 
ventilator-free days. It is unclear whether steroids in this setting 
positively affected patient outcome by minimizing the ongoing 
inflammation produced by the ventilator. There is very limited 
information about steroid administration in patients receiving 
lung protective ventilation.
A variety of steroid dosing regimens have been studied. 
Initially, high doses of methylprednisolone (30 mg intravenously 
every 6 h) to treat early ARDS were investigated but there was no 
mortality benefit (16) nor was there evidence that steroid admin-
istration could prevent ARDS in high risk populations (17–20). 
More recent investigations have focused on low–moderate doses 
of steroids with modest variability in the exact dosing regimen.
Investigation of low–moderate doses of steroids to treat early 
ARDS gained enthusiasm after a post hoc subgroup of patients 
included in a trial of hydrocortisone and fludrocortisone treat-
ment for septic shock (21). This group was somewhat more 
homogeneous than other studies as all patients included had 
secondary ARDS in the setting of sepsis. Approximately 14% 
of this subgroup also had chronic pulmonary diseases. The 
administration of 50 mg of hydrocortisone intravenously every 
6 h for 7 days in conjunction with 50 μg of fludrocortisone daily 
was not associated with any mortality benefit for the group as a 
whole. However, the subgroup of patients who were diagnosed 
with critical-illness related adrenal insufficiency (CIRCI), also 
denoted as non-responders, had a significant difference in mor-
tality with the administration of steroids (53 vs. 75%, 95% CI: 
0.36–0.89, p = 0.013) compared to those who received placebo. 
There were approximately equal numbers of patients who had 
chronic pulmonary disorders in the non-responder placebo and 
non-responder steroid groups. Some have hypothesized that 
ARDS is the pulmonary manifestation of inappropriately low 
endogenous cortisol production for an inflammatory stimulus 
(22). Given that ARDS is a heterogeneous group of patients, 
there may be certain subgroups, such as patients with CIRCI, 
that may benefit from steroids administration for ARDS but that 
conclusion cannot be made from a post hoc analysis of relatively 
small numbers (N = 177) of patients who did not receive the lung-
protective ventilation that is now standard of care.
The most positive study results in favor of treating ARDS with 
steroids is from a small randomized controlled trial of 91 patients 
conducted by Meduri and colleagues specifically to investigate 
the treatment of low–moderate doses of methylprednisolone for 
the treatment of early ARDS (23). This study has significant limi-
tations that are worth discussing in detail. Patients were recruited 
between 1997 and 2002. This study participants appeared to be 
a relatively severely ill group of patients with average positive 
end-expiratory pressure of 12  cm of H2O, PaO2/FiO2 ratio of 
about 120, and lung injury score (LIS) of ~3 upon enrollment. 
The trial compared a regimen of methylprednisolone to placebo. 
The methylprednisolone regimen included a 1  mg/kg loading 
dose followed by a 1  mg/kg/day infusion that was planned for 
14  days with a taper for an additional 14  days. Steroids could 
be decreased more rapidly if patients met the study outcome 
of successful extubation or a decrease in LIS by 1 by day 7 of 
treatment. Patients were randomized in a 2:1 fashion such that 
63 patients were in the steroid arm and 28 were in the control 
group. This study showed significantly positive results in all out-
come measures. Almost 70% of the steroid group had a one-point 
decrease in LIS by day 7 of the study compared to 36% of the 
control group (p = 0.002). Approximately 54% of patients in the 
steroid group extubated successfully by day 7 compared to 25% 
of control patients (p =  0.01). Mortality was also lower in the 
steroid group (24 vs. 43%, p = 0.07). The results of this trial sup-
port ongoing investigation into steroids to treat certain patient 
populations with ARDS but the limitations of the study preclude 
treating all patients with ARDS with routine steroid therapy. For 
example, the methodology used by the authors initially limited 
plateau pressures to 35  cm of H2O and was later changed to 
30 cm of H2O in accordance with the ARDSnet publication (7). 
The actual plateau pressures or tidal volumes received by patients 
are not reported and, thus, introduce potential confounding by 
ventilator-induced lung injury. The overall small number of par-
ticipants and especially the small number of control patients, the 
possible participation of patients with steroid-responsive chronic 
conditions, the outcome measure of extubation rather than 
ventilator-free days, and the lack of utility of LIS as an outcome 
measure (24) could all be addressed in a future trial.
The results of a recent pilot trial cast doubt on the positive 
findings of the Meduri study. Although the cohorts evaluated 
by these two studies are not equivalent, this newer data bring 
equipoise to the question of steroids for ARDS. This small study 
was conducted in South Korea to determine predictive factors 
for response to steroids in patients with moderate-to-severe 
ARDS (25). The study involved 20 patients with mostly moderate 
ARDS by the Berlin criteria. This cohort has a lower severity of 
illness compared to the study by Meduri. The group reported 
using ARDSnet protocol for ventilation but does not report the 
ventilator parameters that participants actually received. All of 
these participants received a methylprednisolone loading dose 
and infusion for the first 14 days of the study that is comparable 
to the dosing used in the Meduri study. The study used the same 
outcome measures of extubation or a one-point decrease in LIS 
by day 7 of steroid therapy to define a group of “responders” 
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and “non-responders.” Fifty percent of the cohort was deemed 
to have a response to steroid therapy. The most interesting part 
of this study is that the authors tried to predict the group of 
responders with biomarkers from serum and bronchoalveolar 
lavage (BAL) specimens that were collected at enrollment and on 
study day 7. Biomarkers collected included serum procalcitonin, 
C-reactive protein (CRP), transforming growth factor-beta 
(TGF-β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-
α), N-terminal pro-B type natriuretic peptide (NT-proBNP). 
Biomarkers from BAL samples included triggering receptor 
expressed on myeloid cells (TREM-1), which has been associated 
with bacterial infection, and procollagen peptide type III, which 
is thought to represent ongoing fibroproliferation in the lung. 
Previous studies performed before lung protective ventilation 
demonstrated higher inflammatory cytokines in BAL samples 
that correlated to the ongoing need for mechanical ventilation 
that was presumed to be from fibroproliferation and also cor-
related with mortality (26, 27). However, in this study, there was 
no significant difference in any of the inflammatory markers or 
procollagen peptide III between responders and non-responders. 
Nor did the investigators find a difference in clinical metrics, 
such as initial oxygenation index, PaO2/FiO2 ratio, or LIS. The 
response rate to steroids was surprisingly low and it is unclear 
whether the poor response rate indicates that fewer patients may 
benefit from steroids than previously hypothesized, or whether 
the investigators identified differences in the “natural history” of 
pulmonary healing between the two different groups. Regardless, 
it is important to acknowledge that despite using the best avail-
able clinical parameters and biomarkers of disease severity, we 
yet cannot identify individuals for the directed use of steroid as 
personalized therapy or for enrollment of an enriched cohort of 
likely steroid responders into future clinical trials.
There has been less investigation into the possible role of 
steroids in PARDS. A pilot trial enrolled 35 pediatric patients 
with an average PaO2/FiO2 ratio of ~150 and compared duration 
of mechanical ventilation in a group receiving steroid to one 
receiving placebo (13). The intervention group received a dif-
ferent steroid regimen than the adult trials. A loading dose of 
2  mg/kg of intravenous methylprednisolone was followed by a 
1 mg/kg methylprednisolone infusion for 7 days and then a taper 
between 7 and 14 days. This represents a somewhat shorter course 
of steroids compared to previous adult studies. Both groups had 
a small, but equal number of patients who may potentially have 
steroid-responsive diseases, including asthmatics and preterm 
infants. The intervention arm had on average lower lung compli-
ance for the first two study days with higher plateau pressures but 
equivalent tidal volumes (average plateau pressure 33 cm H2O vs. 
24 cm H2O, p = 0.006). There was no difference in the duration of 
mechanical ventilation between the groups. The sample size is too 
small to determine if the steroids improved lung compliance that 
enabled the intervention group to extubate at generally the same 
time as the control group, despite what might be more significant 
lung disease.
In contrast to the somewhat optimist results of the previously 
described pediatric feasibility study of methylprednisolone, a 
larger prospective observational cohort pointed toward steroid 
therapy being associated with fewer ventilator-free days and 
increased mortality (6). A group of 283 children who met both 
adult and pediatric definitions of moderate-to-severe ARDS were 
followed throughout their hospital course. Sixty percent of the 
cohort was exposed to steroids for more than 24 h, a criterion 
meant to exclude patients receiving peri-extubation steroids and 
brief courses of “stress dose” steroids. Of the patients who received 
more than 24 h of steroids, 22% of them had a history of reactive 
airway disease. Steroids were initiated on the same day as PARDS 
diagnosis in most patients (IQR 0–1) with a median duration of 
7 days (IQR 5–12 days). Patients received different corticosteroids 
with the most common being hydrocortisone (51%) and meth-
ylprednisolone (41%). Steroid dose was compared using methyl-
prednisolone equivalents with a median cumulative dose of 8 mg/
kg (IQR 4–20 mg/kg) during mechanical ventilation. The average 
patient in this study received ~1 mg/kg of corticosteroids, which 
is similar to the low–moderate dosing in adult studies. Steroid 
exposure greater than 24  h was independently associated with 
fewer ventilator-free days when adjusted for severity of illness, 
immunocompromised status, number of non-pulmonary organ 
failures, reactive airway disease, and worst oxygenation index in 
the first 24 h, maximum vasopressor score in the first 72 h, and 
fluid balance in the first 72 h of PARDS. Surprisingly, the mortal-
ity was higher in the group receiving steroids for greater than 24 h 
compared to the group with no steroid/steroid for less than 24 h 
(17 vs. 8%, p = 0.034, unadjusted analysis). Cumulative steroid 
dose was also associated with increased mortality among patient 
with PARDS. This study has several limitations. The variability 
of the steroid regimens, including the specific corticosteroid, the 
dose, and how the medication was discontinued may influence 
outcomes. Steroids may have been used for different indications 
in patients that are not readily apparent in the reported data. 
Importantly, the cohort design cannot control for unknown 
confounders with statistical analysis. Despite these limitations, 
the difference in mortality that is adjusted for severity of illness 
should make the clinician cautious with the use of steroids for 
PARDS until more robust information is available.
The literature for both pediatric and adult patients with ARDS 
in its current state cannot support routine steroid use within the 
first 72 h. The studies with positive results should encourage the 
medical community to continue to investigate which subgroups 
may benefit from steroids in addition to lung protective ventila-
tion, e.g., patients with P. jirovecii pneumonia (28, 29), well as 
those groups who may suffer additional harm, e.g., patients with 
H1N1 pneumonia (30–32).
TReATMeNT OF LATe ARDS TO 
iNHiBiT FiBROPROLiFeRATiON
During the early phase of ARDS, there is simultaneous activation 
of inflammation, coagulation, and tissue repair mechanisms. Over 
time, some survivors control the level of inflammation and repair 
the pulmonary tissue, returning it to a good level of function. On 
the other hand, some survivors have persistent inflammation and 
a maladaptive repair process involving the deposition of extracel-
lular matrix that leads to ongoing restrictive lung disease. Studies 
have looked at the ability of steroids, which are known to inhibit 
the fibrotic response in addition to anti-inflammatory effects, to 
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improve lung function when patients have failed to extubate by 
day 7 of ARDS with the assumption that this group has significant 
pulmonary fibroproliferation and ongoing inflammation. This 
assumption is supported by a recent publication from a single 
center that routinely obtains open lung biopsy in patients with 
unresolving ARDS that can clinically tolerate the procedure 
(33). The study included 83 adult patients with variable severity 
of disease. The median time to lung biopsy was 8 days. Overall, 
58% of patients with ARDS still on the ventilator at the time of 
lung biopsy had evidence of ongoing diffuse alveolar damage and 
fibroproliferation. These histologic findings were more common 
in patients with severe ARDS as defined by the Berlin criteria. 
Steroid use was not reported.
In 1998, Meduri and colleagues published the results of a small 
randomized controlled trial that supported the use of steroids for 
late ARDS (34). They randomized 24 adults with ongoing ventila-
tor need 7  days after ARDS diagnosis and with little improve-
ment in LIS in a 2:1 fashion to methylprednisolone treatment vs. 
placebo. The dosing of methylprednisolone was higher than the 
dosing used in many of the early ARDS studies. Patients received 
2  mg/kg of intravenous methylprednisolone as a loading dose 
and continued on intermittent dosing every 6  h for a total of 
2 mg/kg/day for 14 days. The steroid was tapered over 18 days 
for a total of 32 days of steroid therapy. The protocol allowed for 
cross-over from the placebo group into the steroid group if there 
was no improvement in LIS or extubation by study day 10. The 
primary outcome was mortality. The study was stopped early for 
significantly better survival in the steroid group – all patients in 
the steroid arm survived and 5 of 8 (60%) of the placebo arm 
died. The study is statistically challenging to interpret with a very 
small control group of only 8. The study has been criticized for 
a high cross-over rate of 50% from the placebo into the steroid 
arm with a significant number of deaths in the placebo group 
occurring after receiving steroids. Additionally, similar to many 
studies for early ARDS, these patients did not receive standard 
lung-protective ventilation leading to the hypothesis that steroids 
may have been treating the ongoing inflammation incurred by 
ventilator-induced lung injury.
A larger randomized controlled trial from the ARDSnet inves-
tigators followed the initial small trial with results that did not 
support routine administration of steroids for ARDS (5). This trial 
enrolled 180 adults with a diagnosis of ARDS that had persistent 
pulmonary infiltrates and ongoing mechanical ventilation for 
7 days. The study failed to recruit the estimated sample size of 400 
despite enrolling patients at 25 hospitals. The protocol for meth-
ylprednisolone was modified from the Meduri study to allow a 
faster taper over 4 days if extubation occurred, but was otherwise 
relatively similar. Mortality was equivalent in both groups. The 
steroid arm had significantly fewer days of mechanical ventilation 
(~7 days vs. 11 days, p < 0.001). However there was a significantly 
higher need for reinstitution of mechanical ventilation in the 
steroid group (20 vs. 6, p = 0.008). Hypotheses to explain a higher 
reintubation rate include recrudescence of pulmonary inflam-
mation in the setting of a rapid steroid taper, steroid-associated 
neuromyopathy, or undiagnosed infection. Of note, there was an 
a priori subgroup analysis of patients who enrolled after 13 days 
of ARDS. This cohort is small with 23 patients in the steroid group 
and 25 in the placebo group. Similar to the study by Meduri, these 
patients had an overall higher mortality (44 vs. 12%). The authors 
concluded that steroid administration after 7 days does not have 
clear benefit and administration of steroids after 14 days may be 
harmful. If steroids are useful for fibroproliferation, there may be 
a window of opportunity for administration where fibroprolifera-
tion may be modified.
In summary, the data from adult patients with late ARDS 
and presumed ongoing fibroproliferation do not show mortality 
benefit. Furthermore, steroids have only a questionable benefit 
in decreasing morbidity; despite decreasing the overall duration 
of mechanical ventilation. There is an associated high rate of 
reintubation and no overall decrease in length of hospital stay 
with the currently studied doses and regimens. Specifically, ster-
oids should not be used as standard of care for pediatric patients 
who still have ongoing need for mechanical ventilation after a 
week based on the adult data. An additional layer of uncertainty 
in younger children with ongoing lung development is whether 
there are similar rates of fibroproliferation and ongoing diffuse 
alveolar damage that are the conceptual basis for steroid therapy.
POSSiBLe LONG-TeRM eFFeCTS 
OF STeROiD TReATMeNT FOR ARDS
As survival has improved for disorders treated in the intensive 
care unit, focus has broadened from hospital markers of good 
outcome to patient function in society several years after 
discharge. Steroids given to treat ARDS have been evaluated 
for short-term pulmonary benefits and mortality in the studies 
reviewed above, but steroid use has also been implicated in ICU-
acquired neuromyopathy contributing to physical impairments 
seen in survivors of ARDS that lasts months if not years, after 
hospital discharge (3, 35–37). Confirming the causality of steroid 
therapy in the development of ICU-acquired neuromyopathy is 
challenging as most studies cannot control for other contributing 
factors to ongoing weakness, such as the use of neuromuscular 
blockade and general immobility while ventilated. Although it 
is impossible to use the current information to help guide the 
decision to give or withhold steroids during early or late ARDS, 
providers should be aware of the controversy around ICU-
acquired neuromyopathy and understand that other currently 
unrecognized long-term consequences of ICU therapy, including 
steroids, may arise over time.
ICU-acquired neuromuscular weakness involves dysfunction 
of the nerves, muscles, or both. Nerves may be functionally 
impaired or completely denervated. Skeletal muscles can have both 
impaired contractility and diminished mass from a combination 
of decreased protein synthesis and increased proteolysis. On the 
one hand, steroids may have direct myotoxicity but, on the other 
hand, steroids may decrease the duration of mechanical ventila-
tion and minimize the contribution of bedrest to ICU-acquired 
weakness. One study of 95 mechanically ventilated patients 
found an odds ratio of nearly 15 (95% CI: 3.2–69.8) for develop-
ment of ICU-acquired neuromyopathy if patients had received 
steroids (38). However, these patients were also sedated to the 
point where they could not follow commands for an average of 
2 weeks. It is unclear whether it is the receipt of corticosteroids or 
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immobilization that is the more important factor in the severity 
of ICU-acquired neuromuscular weakness.
There are two studies that followed patients for a year after 
hospital discharge that found an association between steroid 
receipt and ongoing weakness that support the hypothesis of direct 
myotoxicity from steroids. Herridge and colleagues followed a 
cohort of patients with moderate-to-severe ARDS for 12 months 
(35). This group of 109 patients was a relatively sick cohort with 
a median duration of mechanical ventilation of 21 days that were 
likely not treated with lung protective ventilation as the hospi-
talizations were between 1998 and 2001. This study found the 
absence of corticosteroid treatment the most predictive factor in 
improvement in 6-min walk test during the first 3 months after 
hospital discharge and the strength of this association decreased 
and disappeared over time as might be expected from a slowly 
reversible process. There is a strong possibility of residual 
confounding with the sickest patients that are included in this 
study receiving steroids and then noting worse outcomes in an 
observational cohort. More recently, a cohort of patients from 
various ARDSnet trials were followed at 6 and 12 months after 
hospital discharge (3). The study consisted of 203 patients, most 
of whom met definitions of moderate-to severe ARDS within 72 h 
of admission to the ICU. All patients received lung protective ven-
tilation but steroid administration, neuromuscular blockade, and 
early mobility were not a part of the study protocols. Forty-three 
percent of the cohort received steroids with an average daily dose 
of 52  mg of prednisone equivalents (SD ±  81  mg) and mainly 
used to treat early ARDS (83% received steroids within 72 h of 
mechanical ventilation). Most patients (75%) did not receive 
early mobilization and likely experienced a significant degree of 
immobility. The study reported that corticosteroids, up to a dose 
of 40 mg/day, were associated with increasingly worse physical 
outcome measures but is limited by residual confounding.
Not all follow-up studies of ARDS patients have found an 
association between ICU-acquired weakness and steroids. One 
recently published study of 222 adults with ARDS reported 
no association between cumulative steroid dose and muscle 
weakness at hospital discharge but rather reported that muscle 
strength was diminished by 3–11% for each day of bedrest when 
adjusting for risk factors (36). This study highlights the role that 
mobilization of patients may have in offsetting neuromuscular 
weakness, such that interventions that decrease the duration 
of mechanical ventilation, even steroids, may preserve muscle 
strength after ARDS. Importantly, a review of 128 survivors from 
the ARDSnet trial of steroids for late ARDS used data from a 
randomized controlled trial that controlled for other confound-
ing variables (37). Although the diagnosis of neuromyopathy 
was significantly more common in the group randomized to 
steroids in the ARDSnet study (5), there was no significant dif-
ference between clinician recognition of neuromyopathy during 
the hospitalization between the two groups in the later review of 
survivors (37).
The pediatric literature is very limited in describing 
long-term outcomes for patients with PARDS (39). Children 
have persistent pulmonary impairment in several case series 
summarized by the recent consensus conference on PARDS, 
but neurocognitive outcomes and ability to return to school 
remain research priorities. The adult studies of corticosteroid 
administration contributing to ongoing muscle weakness 
may not capture all of the potential risks of corticosteroids in 
the youngest patients with ongoing lung and neurocognitive 
development.
CONCLUSiON
The summative evidence for steroid administration to the patient 
with ARDS or PARDS falls short of the level needed to support 
routine use for either early or late disease. The patients who meet 
the consensus definitions for ARDS and PARDS continue to be 
a heterogeneous group with subtle differences in pathophysiol-
ogy. The positive signal for steroids in some studies combined 
with higher likelihood of benefit in some subgroups, such as 
those with steroid-responsive underlying disorders, supports 
ongoing research into the appropriate use of steroids for ARDS. 
Perhaps the use of genomics, proteomics, and metabolomics will 
help identify both cohorts with common diagnoses, as well as 
individuals, who will benefit from steroid therapy.
Previous studies of corticosteroid therapy for patients with 
ARDS cannot be directly applied to the care of patients today. 
Various meta-analyses have been published relatively recently 
on the use of steroids for ARDS (30, 40–43). All are problematic 
to interpret because studies of steroids for early and late ARDS 
have been evaluated together although the therapeutic targets 
and patient populations are different. No similar meta-analyses 
exist for steroid therapy in PARDS. Additionally, no single sizable 
study has a complete cohort of participants who receive lung-
protective ventilation and ventilator discontinuation by a strict 
protocol to reduce the potential confounding from ventilator-
induced lung injury. These components of study design are even 
more important for pediatric studies of PARDS where mortality 
is unlikely to be affected by an adjunctive respiratory therapy and 
where ventilator-free days would be a more appropriate short-
term outcome. Studies of steroids in adults with ARDS are likely 
to be generalizable to many older pediatric patients with PARDS 
after reaching lung maturity, especially teenage patients.
The Pediatric Acute Lung Injury Consensus Conference 
(PALICC) agreed that steroids cannot be recommended as 
part of routine care for PARDS (44). While the door is not fully 
closed on steroid therapy for pediatric and adult ARDS, rational 
administration of glucocorticoids for this diagnosis requires 
a reasonable belief that the patient falls in a special cohort of 
steroid responders. The best-defined steroid responders are those 
with ARDS from Pneumocystis pneumonia. The next most likely 
group of steroid responders are patients with underlying steroid-
responsive obstructive lung disease who have biologic reason to 
respond to steroids but have been inadequately studied in the 
setting of concurrent ARDS. These groups together compromise 
a minority of all patients with ARDS/PARDS and steroid admin-
istration should be the exception rather than the rule.
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